A phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

A phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

New therapies are needed to prevent exacerbations, improve quality of life and slow disease progression in bronchiectasis. Inhibition of cathepsin C (CatC) activity has the potential to decrease activation of neutrophil-derived serine proteases in patients with bronchiectasis, thereby reducing airwa...

Full description

Bibliographic Details
Main Authors: Chalmers, James D., Gupta, Abhya, Chotirmall, Sanjay Haresh, Armstrong, April, Eickholz, Peter, Hasegawa, Naoki, McShane, Pamela J., O'Donnell, Anne E., Shteinberg, Michal, Watz, Henrik, Eleftheraki, Anastasia, Diefenbach, Claudia, Sauter, Wiebke
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Journal Article
Language:English
Published: 2024
Subjects:
Medicine, Health and Life Sciences
Cathepsin C Inhibitor
Asthma
Online Access:https://hdl.handle.net/10356/173554

Similar Items

Similar Items